Ainos Grants Global VELDONA License to BioPhoenix; Upfront $600,000, Fees Up to $10 Million

Ainos entered into a Global Exclusive License Agreement with BioPhoenix covering its VELDONA low-dose oral interferon alpha platform for Sjögren’s Disease and thrombocytopenia. The worldwide, transferable license allows BioPhoenix to develop and commercialize the indications and includes options fo…